X

Chief Revenue Officer (CRO)

Remote
1
Users

Chief Revenue Officer (CRO)

Remote (Europe) | Life Sciences SaaS | Series A Growth

Headhunty has been exclusively retained by a Swiss-based life sciences software company to appoint a Chief Revenue Officer (CRO).

Our client operates in the clinical research / CRO technology space, providing a vertical SaaS platform used by pharmaceutical companies, biotech firms, and contract research organizations to manage and optimize clinical trials.

The company has already achieved strong product–market fit and €1–5M ARR and is now preparing for rapid commercial expansion ahead of a planned Series A fundraising within the next 12–18 months.

This role represents a rare opportunity to build and scale the entire commercial organization from the ground up and work directly with the CEO as a strategic partner in the next phase of growth.

The Role

The Chief Revenue Officer will be responsible for designing and executing the companys entire revenue strategy across sales, marketing, partnerships, and go-to-market operations.

Reporting directly to the CEO, the CRO will transform an early commercial foundation into a scalable revenue engine capable of supporting Series A growth and beyond.

This is a hands-on leadership role suited to someone who thrives in high-growth environments and is comfortable combining strategic leadership with direct execution.

Key Responsibilities

Commercial Leadership

  • Build and lead the full revenue organization across sales, marketing, and partnerships

  • Define the commercial strategy and scale predictable revenue growth

  • Own key metrics including ARR, pipeline, win rates, CAC, and revenue retention

Sales Development

  • Design and implement the sales process, playbook, and pricing strategy

  • Personally close strategic deals during the early stage

  • Build and scale a high-performing sales team as revenue grows

Go-to-Market Strategy

  • Define the ideal customer profile and target market segments

  • Position the company competitively within the clinical research technology landscape

  • Identify expansion opportunities across biotech, CROs, and medtech companies

Marketing & Demand Generation

  • Develop the demand generation engine and pipeline creation strategy

  • Establish brand positioning and messaging for the life sciences market

  • Build marketing capabilities internally or through partners

Strategic Partnerships

  • Identify and develop partnerships that accelerate revenue growth

  • Build alliances and channel relationships within the life sciences ecosystem

  • Expand the partner network to support international growth

Series A Growth Mandate

Over the next 12–18 months, the CRO will play a critical role in preparing the company for Series A investment by establishing:

  • Predictable ARR growth and scalable revenue processes

  • A repeatable and measurable sales model

  • A high-performing commercial team

  • Clear go-to-market positioning in the clinical research technology market

  • Investor-grade reporting, forecasting, and revenue metrics

Candidate Profile

Required Experience

  • 8+ years in commercial leadership roles within B2B SaaS

  • Experience selling into life sciences organizations such as CROs, biotech, medtech, or pharma

  • Proven track record of scaling revenue at early-stage SaaS companies

  • Experience building commercial teams from early revenue through scale

  • Strong network within the European life sciences ecosystem

  • Ability to operate as both strategic leader and hands-on deal closer

Preferred Background

  • Experience working in clinical trial software, research platforms, or healthtech SaaS

  • Prior experience supporting venture fundraising or Series A preparation

  • Track record of building revenue through strategic partnerships and alliances

Why This Opportunity?

  • Opportunity to build the commercial organization from day one

  • Direct partnership with the CEO and founding team

  • High-growth company in the rapidly expanding clinical research technology market

  • Significant equity upside ahead of Series A